APOC3, apolipoprotein C3, 345

N. diseases: 153; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome. 26824674 2016
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE These data, therefore, suggest that the APOC3 promoter polymorphisms C-482T and T-455C are associated with the MetS. 17416293 2007
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus. 23542898 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE In the joint analysis, the associations of the WDP and APOC3 rs5128 with MetS risk tended to be dependent on APOC3 3238C>G gene variants (p for interaction = 0.009) in women. 25301527 2014
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE To evaluate the influence of cholesterol ester transfer protein (CETP) TaqIB polymorphism, lipoprotein lipase (LPL) PvuII and HindIII polymorphisms, hepatic lipase (LIPC) G-250A polymorphism and apolipoprotein C-III (APOC3) SstI gene polymorphism on lipid levels in dyslipidemia of the metabolic syndrome, 150 patients with dyslipidemia of metabolic syndrome were included.96 % of patients had type 2 diabetes. 16343038 2006
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE Apolipoprotein A5 gene (APOA5) variants are associated with increased plasma triglycerides, a risk factor for the metabolic syndrome (MS), but a correlation with apolipoprotein C3 (APOC3) genotypes is controversial. 19932084 2010
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE The minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS. 21749608 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE The rs5128 (APOC3) and rs340874 (PROX1) polymorphisms were found to be significantly associated with susceptibility to MetS (P=0.003 and P=0.033, respectively), with odds ratios (ORs) of 4.39 (95% CI=1.66-11.56) and 2.81 (95% CI=1.09-7.27), respectively. 28919193 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Compared with other genotype combinations, the combined effect of APOC3/APOA1 (CC/GA+AA/CT+TT) genotypes showed a further increase in the risk of the MetS in the highest quartile of WDP scores (OR 1, 2·49, 8·73, 6·32, P trend< 0·001, P(interaction)= 0·003). 25653052 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE Single-nucleotide polymorphisms in the genes encoding for IL-6 (g.-634G>C; c.174G>C), TNFα (g.-308G>A), methylenetetrahydrofolate reductase (MTHFR) (c.677C>T), APOC3 (c.3175C>G), and APOA5 (g.-1131T>C) have been implicated in the processes of inflammation and energy intake that take place in the development of MetS manifestations. 21473680 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels. 14563827 2003
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE The Ala54Thr polymorphism in the fatty acid-binding protein 2 (FABP2) gene as well as the T-455C and C-482T polymorphisms in the apolipoprotein C-III (APOC3) gene promoter have been associated with features of the MS in specific populations. 15598690 2005
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE The western DP had a significant interaction with APOC3, APOA1 and MC4R polymorphisms in relation to MetS. 30584439 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE AGT T174M, GNB3 825C>T, and APOC3 -455T>C genotypes were significantly associated with MetS (P = 0.018, 0.0056, and 0.029, respectively) for female adults, whereas FABP2 A54T genotype was associated with MetS (P = 0.040) for female adolescents. 15869758 2006
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE There was no association between the APOC3 -482C>T or APOC3 3238C>G polymorphisms and metabolic syndrome. 18789138 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE ApoE epsilon2/epsilon3/epsilon4 gene polymorphism is a determinant of the relative proportion of apolipoprotein C-III to E. Carriers of the unfavourable E4 allele present the highest ApoCIII/ApoE ratio and are twofold more frequent among individuals affected by MetSyn. 18188530 2007
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE Carriers of > or =1 copy of APOC3 -455C were more likely to have MetS (NCEP ATP III definition) than noncarriers (carrier odds ratio 1.73, 95% CI 1.40 to 2.14, adjusting for age and study group). 18096054 2007
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE ApoC3 is a promising therapeutic target for hypertriglyceridemia in patients with MetS and diabetes. 30723097 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease LHGDN This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the metabolic syndrome. 18509206 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease RGD Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. 16298371 2006